Societal and fiscal gains from HPV vaccination in Poland – return on investment from extending access to HPV vaccination
Rattachement africain : gr, nl, us, lt. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
OBJECTIVE: To evaluate the societal and fiscal impact of extending the current human papillomavirus (HPV) vaccination program in Poland (boys and girls aged 9-14 with average 20% vaccine coverage) by expanding age eligibility (9-17 years) and increasing vaccination coverage. METHODS: A cost-benefit analysis was conducted from both a macroeconomic (societal) and public economic (fiscal) perspective. A dynamic transmission model (DTM) was used to project the incidence and mortality of HPV-related diseases over a 100-year time horizon. Epidemiological outcomes were translated into economic outcomes using societal and fiscal frameworks incorporating productivity losses, tax revenues, and healthcare costs, and were compared with incremental vaccination costs. All costs and benefits were discounted at an annual rate of 3%. RESULTS: Compared with the current national immunization program, extending vaccination to boys and girls aged 9-17 and increasing coverage to 60% is projected to result in incremental reductions of 16% in HPV-related diseases and 13% in deaths. Achieving 90% coverage was associated with reductions of 33% in HPV-related diseases and 27% in deaths. These health gains are estimated to translate into societal benefits of EUR 4.5 billion and EUR 9.8 billion, and fiscal benefits of EUR 2.4 billion and EUR 5.1 billion, under the 60% and 90% coverage scenarios, respectively. Incremental vaccination costs are estimated at EUR 1.1 billion and EUR 2.1 billion for respective coverage scenarios. The benefit-cost analysis indicates that every EUR 1 invested yields returns of EUR 4.2 (societal) and EUR 2.2 (fiscal) at 60% coverage, and EUR 4.6 (societal) and EUR 2.4 (fiscal) at 90% coverage. All results represent incremental gains relative to the existing program. CONCLUSION: Expanding HPV vaccination eligibility and coverage in Poland is expected to generate substantial societal and fiscal returns. Higher vaccination coverage not only reduces the burden of HPV-related diseases and associated mortality but also delivers a strong and sustainable return on investment.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Societal and fiscal gains from HPV vaccination in Poland – return on investment from extending access to HPV vaccination
- Date Crossref
- 09/09/2026
- Éditeur
- Informa UK Limited
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
National and Kapodistrian University of Athens pays non établi dans la noticeUniversité ou école supérieure
-
University of Groningen pays non établi dans la noticeUniversité ou école supérieure
-
Inc. Merck & Co. pays non établi dans la noticeEntreprise
-
MSD (Lithuania) pays non établi dans la noticeEntreprise
-
Market Access Department pays non établi dans la noticeInstitution
-
Global Market Access Solutions Sàrl pays non établi dans la noticeEntreprise
-
Institute of Mother and Child Pharmacoeconomic Department pays non établi dans la noticeStructure de recherche
-
University Groningen pays non établi dans la noticeUniversité ou école supérieure
-
Value & Implementation Outcomes Research pays non établi dans la noticeInstitution
National and Kapodistrian University of Athens, University of Groningen et Merck & Co. — Inc., avec 6 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.